MX2009011359A - Derivados de pirimidinona y sus metodos de uso. - Google Patents

Derivados de pirimidinona y sus metodos de uso.

Info

Publication number
MX2009011359A
MX2009011359A MX2009011359A MX2009011359A MX2009011359A MX 2009011359 A MX2009011359 A MX 2009011359A MX 2009011359 A MX2009011359 A MX 2009011359A MX 2009011359 A MX2009011359 A MX 2009011359A MX 2009011359 A MX2009011359 A MX 2009011359A
Authority
MX
Mexico
Prior art keywords
methods
pyrimidinone derivatives
pyrimidinone
derivatives
gpr119
Prior art date
Application number
MX2009011359A
Other languages
English (en)
Inventor
Bernard R Neustadt
Andrew W Stamford
Samuel Chackalamannil
Hong Liu
Craig D Boyle
Claire M Lankin
Unmesh G Shah
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009011359A publication Critical patent/MX2009011359A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente invención se refiere a derivados de pirimidinona, a composiciones que comprenden un derivado de pirimidinona, y a métodos de uso de los derivados de pirimidinona para tratar o prevenir obesidad, diabetes, una enfermedad metabólica, una enfermedad cardiovascular o un trastorno relacionado con la actividad de GPR119 en un paciente.
MX2009011359A 2007-04-20 2008-04-17 Derivados de pirimidinona y sus metodos de uso. MX2009011359A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92546507P 2007-04-20 2007-04-20
US95332307P 2007-08-01 2007-08-01
PCT/US2008/004938 WO2008130584A1 (en) 2007-04-20 2008-04-17 Pyrimidinone derivatives and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2009011359A true MX2009011359A (es) 2009-11-05

Family

ID=39651245

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011359A MX2009011359A (es) 2007-04-20 2008-04-17 Derivados de pirimidinona y sus metodos de uso.

Country Status (11)

Country Link
US (1) US8318751B2 (es)
EP (1) EP2148870A1 (es)
JP (1) JP2010524941A (es)
CN (1) CN101754961A (es)
AR (1) AR066120A1 (es)
CA (1) CA2684634A1 (es)
CL (1) CL2008001125A1 (es)
MX (1) MX2009011359A (es)
PE (1) PE20090157A1 (es)
TW (1) TW200845996A (es)
WO (1) WO2008130584A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008038768A1 (fr) * 2006-09-28 2008-04-03 Dainippon Sumitomo Pharma Co., Ltd. Composé ayant une structure de pyrimidine bicyclique et composition pharmaceutique comprenant le composé
JP2010524944A (ja) * 2007-04-20 2010-07-22 シェーリング コーポレイション テトラヒドロピリド［４，３−ｄ］ピリミジノン誘導体およびそれらの使用方法
CA2724426A1 (en) * 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
JP2011528369A (ja) 2008-07-16 2011-11-17 シェーリング コーポレイション 二環式ヘテロ環誘導体およびそれらの使用方法
AU2009270971A1 (en) 2008-07-16 2010-01-21 Schering Corporation Bicyclic Heterocycle Derivatives and use thereof as GPR119 modulators
TW201109327A (en) * 2009-05-28 2011-03-16 Otsuka Pharma Co Ltd Heterocyclic compound
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PT3176170T (pt) 2012-06-13 2019-02-05 Incyte Holdings Corp Compostos tricíclicos substituídos como inibidores de fgfr
JP2015522080A (ja) 2012-07-11 2015-08-03 エルセリクス セラピューティクス インコーポレイテッド スタチン、ビグアナイド、およびさらなる薬剤を含む心血管代謝性リスクを減少させるための組成物
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
PE20152033A1 (es) 2013-04-19 2016-01-21 Incyte Holdings Corp Heterociclos bicicliclos como inhibidores de fgfr
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3617205B1 (en) 2015-02-20 2021-08-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
EP3496720A4 (en) * 2016-08-12 2020-06-10 Nanjing Gator Meditech Company, Ltd. PROTEIN KINASE REGULATORS
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN112867716A (zh) 2018-05-04 2021-05-28 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
CA3099116A1 (en) 2018-05-04 2019-11-07 Incyte Corporation Salts of an fgfr inhibitor
GB2596010B (en) * 2019-02-11 2023-03-01 Madera Therapeutics Llc Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
WO2020176654A1 (en) 2019-02-27 2020-09-03 Madera Therapeutics, LLC Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
CN110156629A (zh) * 2019-05-30 2019-08-23 广州药本君安医药科技股份有限公司 丙卡巴肼的合成方法
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
JOP20220083A1 (ar) 2019-10-14 2023-01-30 Incyte Corp حلقات غير متجانسة ثنائية الحلقة كمثبطات لـ fgfr
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
CN115243689A (zh) * 2020-03-11 2022-10-25 东亚St株式会社 用于预防或治疗糖尿病和与之相关的代谢疾病的药物组合物
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2280435T3 (es) * 2000-12-01 2007-09-16 Astellas Pharma Inc. Metodo de exploracion de remedios para la diabetes.
US20070066590A1 (en) * 2003-02-24 2007-03-22 Jones Robert M Phenyl-and pyridylpiperidine-derivatives as modulators of glucose metabolism
EP2287165A3 (en) * 2003-07-14 2011-06-22 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2008038768A1 (fr) 2006-09-28 2008-04-03 Dainippon Sumitomo Pharma Co., Ltd. Composé ayant une structure de pyrimidine bicyclique et composition pharmaceutique comprenant le composé

Also Published As

Publication number Publication date
CA2684634A1 (en) 2008-10-30
CN101754961A (zh) 2010-06-23
EP2148870A1 (en) 2010-02-03
US20100113487A1 (en) 2010-05-06
TW200845996A (en) 2008-12-01
PE20090157A1 (es) 2009-03-27
WO2008130584A1 (en) 2008-10-30
AR066120A1 (es) 2009-07-22
CL2008001125A1 (es) 2008-10-24
JP2010524941A (ja) 2010-07-22
US8318751B2 (en) 2012-11-27

Similar Documents

Publication Publication Date Title
MX2009011359A (es) Derivados de pirimidinona y sus metodos de uso.
MX2010004450A (es) Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
MX2009011358A (es) Derivados de pirimidinona y metodos para su uso.
MX2009011357A (es) Derivados de tetrahidropirido[4,3-d] pirimidinona y metodos de uso de los mismos.
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
PH12016501607A1 (en) Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia
MX2009010894A (es) Derivados de 3-hidroquinazolin-4-ona para utilizarse como inhibidores de estearoil-coa-desaturasa.
MX2009009416A (es) Derivados de bencimidazol y sus metodos de uso.
MX342423B (es) Metodos para usar inhibidores de cotransportadores 1 y 2 de glucosa y sodio.
JO2756B1 (en) The second preparation of aqueous pyrimidnon containing 4- (4-ciano-2-2 thiourail) and its use)
IL193996A0 (en) Neuromedin u receptor agonists and uses thereof
MX2013004699A (es) Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.
MX2010004494A (es) Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios.
GB2465677B (en) Non-systemic delivery of satiogens for use in the treatment of obesity and/or diabetes
TN2011000416A1 (en) Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient
TN2011000176A1 (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
MX2020012868A (es) Metodos y composiciones para trastornos del sue?o y otros trastornos.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
WO2010049678A3 (en) Treatment of energy utilization diseases
IL202269A0 (en) Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
MX2009009417A (es) Piperidinil-piperidina y piperazinil-piperidina para uso en el tratamiento de diabetes o dolor.
MX2009011062A (es) Derivados de pirimidindiona y sus metodos de uso.
IL212707A0 (en) Compounds, pharmaceutical composition and methods for use in treating metabolic disorders
JO2645B1 (en) Vehicles